Kelyniam Global, Inc.

Equities

KLYG

US4883591004

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 07:00:00 28/05/2024 pm IST			5-day change	1st Jan Change
0.056 ^USD	-4.60%		-6.67%	-8.94%

02/04	Kelyniam Global Announces NEOS Surgery Cranial LOOP? Fixation System Receives 510(k) Clearance from the FDA for use with Finceramica's CustomizedBone? Hydroxyapatite Cranial Implant	CI
17/03	Kelyniam Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

August 08, 2019 at 02:20 pm IST

Kelyniam Global, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced sales was USD 537,200. Operating loss was USD 3,645. Net loss was USD 14,901.

Latest news about Kelyniam Global, Inc.

Kelyniam Global Announces NEOS Surgery Cranial LOOP? Fixation System Receives 510(k) Clearance from the FDA for use with Finceramica's CustomizedBone? Hydroxyapatite Cranial Implant	02/04	CI
Kelyniam Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/03	CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	11/12	CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	18/23/18	CI
Kelyniam Global, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	14/22/14	CI
Singular Health Group Ltd Appoints Kelyniam Global, Inc. and CG1 Solutions as Agents	09/22/09	CI
Kelyniam Global, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	08/22/08	CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	09/22/09	CI
Kelyniam Global, Inc. Provides Earnings Guidance for the Year 2022	14/22/14	CI
Kelyniam Global, Inc., Announces Strategic Licensing Agreement with Fin-ceramica faenza spa to Market Hydroxyapatite Cranial Implant in the U.S	22/21/22	CI
United States Patent and Trademark Office Issues Notification For Patent Covering the Kelyniam Global's Integrated Fixation Tabs, Currently Marketed as Ifs Tabs or Kwiktabs	02/21/02	CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	09/21/09	CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	19/21/19	CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2020	17/20/17	CI
Kelyniam Global, Inc. Not to Provide Financial Results Guidance for the Fourth Quarter of 2020	16/20/16	CI
Kelyniam Global, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	24/20/24	CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	19/20/19	CI
Kelyniam Global Provides Earnings Guidance for the Second Quarter of 2020	18/20/18	CI
Kelyniam Global, Inc. Announces Executive Appointments	07/20/07	CI
Kelyniam Global Announces Distribution Agreement with SurgicalOne	17/19/17	CI
Kelyniam Global, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2019	16/19/16	CI
Kelyniam Global, Inc. Reports Earnings Results for the Half Year Ended June 30, 2019	19/19/19	CI
Kelyniam Global, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	08/19/08	CI
Kelyniam Global Announces Distribution Agreement with Bioplate	09/19/09	CI

Chart Kelyniam Global, Inc.

Duration

Period

More charts

Company Profile

Kelyniam Global, Inc. is a custom design-to-build medical device manufacturing company. The Company specializes in the delivery of cranial implant technologies to neurologically dependent patients. The Company is engaged in the production of custom prosthetics utilizing computer-aided design and computer-aided manufacturing of medical-grade polymers. Its Engineering Division uses Bio-Computer Aided Design (CAD) Computer Aided Manufacturing (CAM) technology to provide replicated cranial implants to replace damaged bone structures. Its product, PEEK-Optima, is engineered for biocompatibility. Derived from the patientâs computed tomography (CT) data, the Companyâs 3D BIO-CAD/CAM software is used to transfer the details found on the edge of the defect directly to the implant edge. Its K-Plans include ke24, ke72 and kp5day. The Companyâs emergency plan, ke24, provides precision-replicated, patient-specific cranial implants in approximately 24 hours.

Sector

Advanced Medical Equipment & Technology

Calendar

24/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
KELYNIAM GLOBAL, INC.	-8.94%	17.45L
THERMO FISHER SCIENTIFIC	+7.87%	22TCr
DANAHER CORPORATION	+11.83%	19TCr
INTUITIVE SURGICAL, INC.	+18.87%	14TCr
BOSTON SCIENTIFIC CORPORATION	+30.03%	11TCr
SIEMENS HEALTHINEERS AG	+2.32%	6.52TCr
EDWARDS LIFESCIENCES CORPORATION	+14.15%	5.3TCr
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.68%	5.03TCr
AGILENT TECHNOLOGIES, INC.	+6.60%	4.42TCr
GE HEALTHCARE TECHNOLOGIES INC.	+1.85%	3.64TCr

Other Advanced Medical Equipment & Technology